After a rough stretch, mRNA gets a boost — at least for now Experts hope the success of a cancer vaccine using the technology can rehabilitate the field By Angus ChenAug. 31, 2026 Cancer Reporter

https://www.statnews.com/2026/08/31/mrna-cancer-vaccine-intersects-politics-medicine/ Can cancer vaccines thaw skepticism of mRNA? After years of political backlash against mRNA vaccines, the field’s researchers believe Moderna and Merck’s positive cancer vaccine readout might help turn the tides for the technology — and perhaps even soften some of the broader stigma around vaccines. That stigma has had real consequences: The Trump administration pulled back hundreds of millions of dollars for mRNA research in infectious diseases, and some cancer vaccine companies have actually stopped using the word “vaccine” altogether. But the approval of the Moderna-Merck therapy could open the door to a much broader wave of cancer vaccines, including personalized products as well as off-the-shelf shots targeting common cancer proteins like KRAS or HPV. And mRNA, which can be rapidly programmed to produce different proteins, may be particularly well suited to the task. “I don’t know how this will be received among parts of our society that have become suspicious of the word ‘vaccine.’ There’s a possibility that people will say, ‘Oh, if we can vaccinate against cancer, that’s good,’” said Ryan Sullivan, a Mass General Brigham melanoma physician and immunologist who has worked with Moderna. “Maybe that will thaw some of the stigma around vaccines. I don’t think it’ll fix all of it, but maybe just a little bit helps us think of ‘vaccine’ not as a dirty word, ‘mRNA’ as not a four-letter word.” https://www.statnews.com/2026/08/19/mrna-cancer-vaccine-trial-melanoma-merck-moderna/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-_d9XAbIwD84KLgIzPkSk9ZszRpaM94ZuvFaoZ1jZZFzOYkmevUzMoJgEUg7qcin9Eh7czCX9et_dHta6sesBHn73IAwQ&_hsmi=436067550&utm_content=436067550&utm_source=hs_email